ALSA Ventures
VC Fund
London, United Kingdom
ALSA Ventures is a London based international life science investor focused on novel therapeutics.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries ALSA Ventures invests in
Stages ALSA Ventures invests in
Countries ALSA Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series B
- $16M–$41M
Investment Focus
Industry
- Biotechnology 4 (67%)
- Therapeutics 3 (50%)
- Life Science 2 (33%)
- Apps 1 (17%)
- Genetics 1 (17%)
Stage
- Seed 2 (33%)
- Series A 2 (33%)
- Series B 1 (17%)
Country
- United Kingdom 2 (33%)
- Belgium 1 (17%)
- Bangladesh 1 (17%)
- Switzerland 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Graeme Martin
Chief Investment Officer
|
Chief Investment Officer | Total investments: 11 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ReproNovo
|
ReproNovo is providing patients all over the world with significant improvement by developing cutting-edge therapeutic solutions for uterine disorders including adenomyosis and for male and female infertility. | $65M / Series A / May 21, 2025 | |
Epsilogen
|
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $16.3M / Series B / Sep 09, 2024 | |
Jatri
|
Jatri is the fastest growing technology company in Bangladesh with a mission to bring reliable transport to everyone, everywhere at the touch of a button. We are offering a mobility-as-a-service platform that enhances bus system reliability and quality. | Series A / Apr 15, 2023 | |
|
Epsilogen
|
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $41.2M / Series B / Mar 02, 2022 | |
Promatix
|
Promatix is a biotechnology company. They develop a pipeline of novel therapeutics. They identify and validate novel drug targets at a protein level using TxPro. | Seed / Mar 08, 2021 | |
Montis Biosciences
|
Montis Biosciences is develops novel immune-oncology therapeutics targeting the intersection between vascular dysfunction and immune suppression to treat solid tumours. | $9.1M / Seed / Feb 20, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does ALSA Ventures invest in?
ALSA Ventures invests primarily in Biotechnology, Therapeutics and Life Science startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is ALSA Ventures's check size?
ALSA Ventures typically joins rounds of $16M–$41M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds ALSA Ventures participates in.
How do I contact ALSA Ventures?
Public channels for ALSA Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at ALSA Ventures?
The team at ALSA Ventures includes Graeme Martin (Chief Investment Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
